[Case-control study evaluating the incidence of hyperhomocysteinemia in cancer patients in an internal medicine department]

N Falvo; F Ghiringhelli; S Berthier; B Bonnotte; B Lorcerie

doi:10.1016/j.revmed.2007.04.003

[Case-control study evaluating the incidence of hyperhomocysteinemia in cancer patients in an internal medicine department]

Rev Med Interne. 2007 Aug;28(8):520-5. doi: 10.1016/j.revmed.2007.04.003. Epub 2007 May 11.

[Article in French]

Authors

N Falvo¹, F Ghiringhelli, S Berthier, B Bonnotte, B Lorcerie

Affiliation

¹ Service de médecine interne et immunologie clinique, hôpital du Bocage, 2, boulevard de Lattre-de-Tassigny, 21030 Dijon cedex, France. nicolas.falvo@chu-dijon.fr

PMID: 17537549
DOI: 10.1016/j.revmed.2007.04.003

Abstract

Purpose: Cancer is a cause of venous thromboembolism. However, the physiopathology remains unknown. Hyperhomocysteinemia could be a promoting factor.

Method: We built a case-control study of 65 patients followed for 2 years to compare levels of homocystéinémie in cancer bearing patients with that in matched cancer free control patients.

Results: Fifty per cent of cancer bearing patients had significantly increased blood serum levels of homocystéine (P=0.006). This increase did not correlate with any deficiency in blood serum levels of folate or vitamin B12.

Conclusion: High levels of homocystéinémie could be linked to tumor proliferation.

Publication types

English Abstract

MeSH terms

Adult
Aged
Aged, 80 and over
Case-Control Studies
Female
Follow-Up Studies
Homocysteine / blood*
Humans
Hyperhomocysteinemia / blood*
Male
Middle Aged
Neoplasms / blood*

Substances

Homocysteine